EDWARDS LIFESCIENCES CORPORATION |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 128.4 BRL | +14.59% |
|
+2.07% | +38.02% |
| 07-02 | Evercore ISI Adjusts Price Target on Edwards Lifesciences to $91 From $89, Maintains In-line Rating | MT |
| 07-01 | Edwards Lifesciences Corporation(NYSE:EW) added to Russell 1000 Value Index | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analyst opinion has improved significantly over the past four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 34.53 and 29.37 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +38.02% | 54.98B | - | ||
| +0.67% | 204B | B | ||
| +4.20% | 178B | B- | ||
| +28.65% | 156B | B- | ||
| +31.79% | 113B | A- | ||
| +1.18% | 64.26B | A- | ||
| -1.86% | 47.44B | B+ | ||
| -9.02% | 36.7B | A | ||
| -0.44% | 34.84B | - | ||
| +10.05% | 27.82B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- EW Stock
- E1WL34 Stock
- Ratings Edwards Lifesciences Corporation
